表紙
市場調査レポート

Sorrento Therapeutics, Inc. の製品パイプライン分析

Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 320383
出版日 ページ情報 英文 69 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
Sorrento Therapeutics, Inc. の製品パイプライン分析 Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016
出版日: 2016年06月30日 ページ情報: 英文 69 Pages
概要

Sorrento Therapeutics, Inc. は米国に本社を置くバイオ製薬企業です。癌および関連の疼痛を治療するための低分子治療薬、抗体薬物複合体(ADC)、抗体薬の開発を行っています。パイプライン製品には、ナノ粒子パクリタキセルであり、転移性乳癌・膵臓癌・非小細胞肺癌治療薬のCynviloqがあります。

当レポートでは、Sorrento Therapeutics, Inc. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Sorrento Therapeutics, Inc. の基本情報

  • Sorrento Therapeutics, Inc. の概要
  • 主要情報
  • 企業情報

Sorrento Therapeutics, Inc. :R&Dの概要

  • 主な治療範囲

Sorrento Therapeutics, Inc. :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Sorrento Therapeutics, Inc. :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Sorrento Therapeutics, Inc. :薬剤プロファイル

  • IG-002
  • paclitaxel-loaded polymeric micelle
  • resiniferatoxin
  • Antibody Drug Conjugate to Target CCR5 for Oncology
  • Biosimilar to Target CD20 for Oncology
  • Monoclonal Antibody for Oncology
  • Monoclonal Antibody to Inhibit Ghrelin for Obesity
  • Small Molecules to Inhibit c-Myc for Cancer
  • STI-001
  • STI-A020X
  • STIA-050X
  • STIA-100X
  • STIA-1010
  • STIA-1011
  • STIA-1012
  • STIA-1014
  • STIA-1110
  • STIA-120X
  • STIA-160X
  • STIA-220X
  • STIA-230X
  • STIB-010X
  • STIB-0201
  • STIB-030X
  • STIB-120X
  • STIB-150X
  • STIC-0205
  • STIC-020X
  • STID-0168
  • STID-0602
  • Clostridium difficile vaccine
  • Monoclonal Antibodies for Clostridium difficile
  • Monoclonal Antibodies for Hepatitis C

Sorrento Therapeutics, Inc. :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Sorrento Therapeutics, Inc. :最新のパイプライン情報

Sorrento Therapeutics, Inc. :開発休止中の製品

Sorrento Therapeutics, Inc. :開発が中止されたパイプライン製品

Sorrento Therapeutics, Inc. :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08079CDB

Summary

Global Markets Direct's, 'Sorrento Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Sorrento Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sorrento Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sorrento Therapeutics, Inc.
  • The report provides overview of Sorrento Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sorrento Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sorrento Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sorrento Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sorrento Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sorrento Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sorrento Therapeutics, Inc. Snapshot
    • Sorrento Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Sorrento Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sorrento Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Sorrento Therapeutics, Inc. - Pipeline Products Glance
    • Sorrento Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sorrento Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sorrento Therapeutics, Inc. - Drug Profiles
    • Cellular Immunotherapy to Target CEA for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PD-L1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PSMA for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BA-0702
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBA-0710
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target c-KIT for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD123 for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target CD33 for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target GD3 for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target HER-2 for Glioblastoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target HER2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target IL13R Alpha2 for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MUC-16 for Ovarian Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target ROR1 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit CD47 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Ghrelin for Obesity
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target EGFR and Inhibit PD-L1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STI-600
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-0168
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-1011
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-1012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-1014
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-1015
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIA-1110
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIB-0201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STIC-0205
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STID-0602
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clostridium difficile vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Clostridium difficile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Hepatitis C
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit WISP1 for Idiopathic Pulmonary Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STI-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sorrento Therapeutics, Inc. - Pipeline Analysis
    • Sorrento Therapeutics, Inc. - Pipeline Products by Target
    • Sorrento Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Sorrento Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Sorrento Therapeutics, Inc. - Recent Pipeline Updates
  • Sorrento Therapeutics, Inc. - Dormant Projects
  • Sorrento Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • paclitaxel
  • Sorrento Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sorrento Therapeutics, Inc., Key Information
  • Sorrento Therapeutics, Inc., Key Facts
  • Sorrento Therapeutics, Inc. - Pipeline by Indication, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016
  • Sorrento Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Sorrento Therapeutics, Inc. - Phase II, 2016
  • Sorrento Therapeutics, Inc. - Phase I, 2016
  • Sorrento Therapeutics, Inc. - Preclinical, 2016
  • Sorrento Therapeutics, Inc. - Discovery, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Target, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Sorrento Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Sorrento Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • Sorrento Therapeutics, Inc. - Dormant Developmental Projects,2016
  • Sorrento Therapeutics, Inc. - Discontinued Pipeline Products, 2016
  • Sorrento Therapeutics, Inc., Subsidiaries

List of Figures

  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Sorrento Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Sorrento Therapeutics, Inc. - Partnered Products in Pipeline, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • Sorrento Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2016
  • Sorrento Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top